Hydronephrosis

Hydronephrosis is a pathological condition characterized by progressive dilation of the renal pelvis and calyces due to impaired urine outflow, leading to increased intrapelvic pressure, renal parenchymal atrophy, and ultimately renal failure if untreated. It is a structural and functional disorder of the urinary tract, often unilateral but can be bilateral, and may be acute or chronic. The condition is classified based on the severity of pelvic dilation (mild, moderate, severe) and the degree of parenchymal loss. In veterinary medicine, hydronephrosis is a common sequel to ureteral obstruction, vesicoureteral reflux, or functional urinary stasis. The systemic relevance includes potential progression to chronic kidney disease (CKD), hypertension, and electrolyte imbalances. Early detection and intervention are critical to preserve renal function.

The primary causes of hydronephrosis in dogs and cats include: (1) Ureteral obstruction due to urolithiasis (calcium oxalate, struvite, urate, cystine), which is the most common cause, especially in cats with distal ureteral stones; (2) Neoplasia of the ureter, bladder, prostate, or retroperitoneum (e.g., transitional cell carcinoma, lymphoma, leiomyosarcoma); (3) Strictures of the ureter secondary to trauma, surgery, or chronic inflammation; (4) Congenital anomalies such as ureteral stenosis, ectopic ureter, or ureterocele; (5) Extrinsic compression from abdominal masses (e.g., pyometra, granulomas, abscesses, or enlarged lymph nodes); (6) Functional obstruction due to neurogenic bladder dysfunction or detrusor-urethral dyssynergia; (7) Iatrogenic causes including accidental ligation of the ureter during ovariohysterectomy or other pelvic surgery; (8) Retroperitoneal fibrosis or adhesions; (9) Vesicoureteral reflux leading to functional obstruction; (10) In rare cases, parasitic infections (e.g., Dioctophyma renale) can cause ureteral obstruction. The underlying mechanism involves increased intrapelvic pressure, which impairs renal blood flow, reduces glomerular filtration rate (GFR), and triggers inflammatory and fibrotic changes in the renal parenchyma.

Hydronephrosis can occur in any breed, age, or sex of dogs and cats, but certain predispositions exist. In cats, ureteral obstruction is more common in middle-aged to older animals, with a slight female predominance due to a higher incidence of calcium oxalate uroliths. Breeds predisposed to urolithiasis include Miniature Schnauzers, Bichon Frises, Lhasa Apsos, and Yorkshire Terriers for struvite and calcium oxalate stones. In dogs, hydronephrosis is often associated with neoplasia, particularly transitional cell carcinoma in breeds like Scottish Terriers, Shetland Sheepdogs, and Beagles. Congenital forms may be seen in young animals, with a higher incidence in certain breeds such as the Siberian Husky (ectopic ureters) and the Golden Retriever (ureteral stenosis). Geographic variations exist, with urolithiasis more common in regions with hot climates due to concentrated urine. The overall incidence in the general veterinary population is not well documented, but it is a relatively common finding in referral centers, especially in cats with acute kidney injury.

The pathophysiology of hydronephrosis begins with obstruction of urine flow, leading to increased pressure within the renal pelvis. This pressure is transmitted to the renal tubules, reducing the net filtration pressure and GFR. Within hours, renal blood flow decreases due to vasoconstriction, and inflammatory mediators such as prostaglandins and cytokines are released. If obstruction persists, the renal parenchyma undergoes progressive atrophy due to ischemia, tubular cell apoptosis, and interstitial fibrosis. The medulla is particularly vulnerable, and chronic obstruction leads to irreversible loss of nephrons. In unilateral obstruction, the contralateral kidney undergoes compensatory hypertrophy, but if both kidneys are affected, acute renal failure can ensue. Additionally, the accumulation of urine in the pelvis creates a favorable environment for bacterial growth, leading to pyelonephritis. Systemic effects include activation of the renin-angiotensin-aldosterone system (RAAS), causing hypertension, and impaired concentrating ability, leading to polyuria and polydipsia. Chronic hydronephrosis can also result in hyperkalemia and metabolic acidosis due to reduced distal tubular function.

Predisposing factors for hydronephrosis include: (1) Urolithiasis: high dietary intake of calcium, oxalate, or purines; low water intake; urine pH abnormalities; and urinary tract infections (UTIs) that promote stone formation. (2) Neoplastic conditions: older age, certain breeds, and exposure to environmental carcinogens (e.g., herbicides for transitional cell carcinoma). (3) Congenital anomalies: genetic predisposition, teratogenic insults during gestation. (4) Trauma: pelvic fractures, abdominal trauma, or iatrogenic injury during surgery. (5) Retroperitoneal disease: pancreatitis, retroperitoneal abscesses, or fibrosis. (6) Neurological disorders: spinal cord disease, sacral nerve damage, or dysautonomia. (7) Medications: drugs that decrease ureteral peristalsis (e.g., anticholinergics) or increase urine crystallinity (e.g., sulfonamides). (8) Chronic urinary tract infections: leading to stricture formation or uroliths. (9) Obesity: associated with increased intra-abdominal pressure and urinary stasis. (10) Inadequate water intake: leading to concentrated urine and stone formation.

Clinical signs of hydronephrosis vary depending on the severity and duration of obstruction. In peracute cases (hours to days), signs may include acute abdominal pain, vomiting, lethargy, and anuria or oliguria if bilateral. In subacute to chronic cases, signs are often subtle and may include polyuria, polydipsia, hematuria, dysuria, or recurrent UTIs. Physical examination may reveal a palpable abdominal mass (enlarged kidney), pain on renal palpation, or signs of uremia (e.g., oral ulcers, dehydration, weight loss). In cases of complete bilateral obstruction, acute renal failure manifests with severe depression, vomiting, and electrolyte disturbances. Chronic unilateral hydronephrosis may be asymptomatic until the contralateral kidney fails. In cats, signs may be vague, such as anorexia, vomiting, and lethargy. Hypertension may be present, leading to retinal detachment or neurological signs. If pyelonephritis is superimposed, fever and leukocytosis may be observed.

Differential diagnoses for hydronephrosis include: (1) Renal cysts: simple or polycystic kidney disease, which can cause renal enlargement but typically no pelvic dilation; ultrasound shows anechoic cavities without communication with the pelvis. (2) Perinephric pseudocysts: fluid accumulation around the kidney, often due to trauma or inflammation; imaging shows a fluid-filled sac surrounding the kidney. (3) Renal neoplasia: primary or metastatic tumors can cause renomegaly; ultrasound may show a mass with altered echogenicity, and fine-needle aspiration or biopsy is diagnostic. (4) Pyelonephritis: inflammation of the renal pelvis and parenchyma, which can cause pelvic dilation but usually with echogenic debris and signs of infection; urine culture is positive. (5) Renal abscess: localized pus collection within the kidney, often secondary to hematogenous spread; imaging shows a cavitary lesion with thick walls. (6) Compensatory hypertrophy: unilateral renal enlargement due to contralateral disease; no pelvic dilation. (7) Ureteral ectopia: congenital malposition of the ureteral orifice, causing urinary incontinence and possibly hydronephrosis; diagnosed by CT or cystoscopy. (8) Retroperitoneal mass: such as sarcoma or granuloma, causing extrinsic compression; imaging reveals a mass adjacent to the ureter. (9) Bladder neoplasia: transitional cell carcinoma at the trigone can obstruct the ureters; cystoscopy or contrast imaging is needed. (10) Neurogenic bladder: functional obstruction due to neurological disease; urodynamic studies may be required.

The diagnostic approach to hydronephrosis should be systematic: (1) History and physical examination: identify risk factors, clinical signs, and palpable renal enlargement. (2) Baseline bloodwork: complete blood count (CBC), serum biochemistry (including creatinine, BUN, electrolytes, and SDMA), and urinalysis with culture. (3) Abdominal radiography: may reveal renomegaly, uroliths, or loss of abdominal detail. (4) Abdominal ultrasonography: the gold standard for initial diagnosis; assess renal size, pelvic dilation, ureteral diameter, and presence of uroliths or masses. Doppler ultrasound can evaluate renal blood flow. (5) If hydronephrosis is confirmed, further imaging to identify the cause: contrast radiography (excretory urography) or computed tomography (CT) with intravenous contrast is highly sensitive for ureteral obstruction. (6) In cases of suspected neoplasia, fine-needle aspiration or biopsy of the renal mass or ureteral lesion. (7) Cystoscopy or ureteroscopy may be used to visualize the lower urinary tract. (8) Renal scintigraphy or measurement of GFR (e.g., iohexol clearance) can quantify functional impairment. (9) If acute obstruction is suspected, emergency decompression via nephrostomy tube or ureteral stent may be both diagnostic and therapeutic. (10) In chronic cases, assess for concurrent CKD using IRIS staging.

Laboratory findings in hydronephrosis are variable. In acute unilateral obstruction, CBC may be normal or show mild stress leukogram. In chronic cases, non-regenerative anemia may be present due to CKD. Serum biochemistry often reveals elevated creatinine and BUN if bilateral or if the contralateral kidney is compromised. SDMA is a more sensitive marker of early renal dysfunction. Electrolyte abnormalities include hyperkalemia, hyperphosphatemia, and metabolic acidosis in advanced cases. Urinalysis may show isosthenuria (USG < 1.030 in dogs, < 1.035 in cats), hematuria, pyuria, and proteinuria. Urine culture is essential to rule out infection. In cases of pyelonephritis, urine sediment may show bacteria and white blood cells. Blood gas analysis may reveal metabolic acidosis. Biomarkers such as symmetric dimethylarginine (SDMA) are useful for early detection of decreased GFR. In neoplastic cases, tumor markers (e.g., urinary bladder tumor antigen) may be elevated. If hypertension is present, serum aldosterone and renin levels may be increased.

Imaging is crucial for diagnosis and management. Abdominal radiography may show renomegaly (kidney length > 2.5 times L2 vertebral body length in dogs) and radiopaque uroliths. Ultrasonography is the primary modality: hydronephrosis appears as an anechoic, fluid-filled renal pelvis with varying degrees of pelvic dilation. The renal parenchyma may be thinned, and the ureter may be dilated proximal to the obstruction. Color Doppler can assess renal arterial flow, which may be reduced in chronic cases. In cats, a distended ureter (> 2.5 mm) is suggestive of obstruction. Contrast-enhanced CT (excretory urography) provides detailed anatomy and can identify the exact site of obstruction, including ureteral stones, strictures, or masses. CT is superior to ultrasound for detecting small uroliths and retroperitoneal disease. Magnetic resonance imaging (MRI) is rarely used but can be helpful for soft tissue characterization. In cases of suspected vesicoureteral reflux, voiding cystourethrography may be performed. Endoscopy (cystoscopy) allows direct visualization of the ureteral openings and can be used for stent placement.

Cytological and histopathological evaluation is indicated when neoplasia or severe inflammatory disease is suspected. Fine-needle aspiration (FNA) of the renal pelvis or a mass can be performed under ultrasound guidance. The aspirate may contain inflammatory cells (neutrophils, macrophages) in pyelonephritis, or neoplastic cells in cases of transitional cell carcinoma or lymphoma. Fluid analysis of the urine from the renal pelvis may show a transudate or exudate depending on the cause. Histopathology of renal biopsies reveals tubular atrophy, interstitial fibrosis, and glomerulosclerosis in chronic hydronephrosis. The renal pelvis may show transitional cell hyperplasia or metaplasia. Special stains (e.g., Masson's trichrome for fibrosis, Gram stain for bacteria) can aid in diagnosis. In cases of urolithiasis, stone analysis (e.g., X-ray diffraction) is essential for preventive management.

Treatment of hydronephrosis depends on the underlying cause and the degree of renal dysfunction. Emergency stabilization is required for acute bilateral obstruction or severe azotemia: intravenous fluid therapy (e.g., 0.9% NaCl or balanced crystalloids) to correct dehydration and electrolyte imbalances, and management of hyperkalemia (e.g., calcium gluconate, insulin-dextrose, sodium bicarbonate). Definitive treatment aims to relieve obstruction. Medical management may be attempted for small uroliths (< 3 mm in cats) using diuresis and antispasmodics (e.g., prazosin, tamsulosin) to promote passage. However, surgical or interventional options are often necessary: (1) Ureteral stent placement via cystoscopy or surgery; (2) Subcutaneous ureteral bypass (SUB) device in cats; (3) Ureterotomy or ureteroneocystostomy for stones or strictures; (4) Nephrectomy if the kidney is non-functional and the contralateral kidney is healthy. In cases of neoplasia, surgical excision or chemotherapy (e.g., mitoxantrone for transitional cell carcinoma) may be considered. Supportive care includes dietary modification (e.g., renal diet, low-protein, low-phosphorus), management of hypertension (e.g., amlodipine, enalapril), and treatment of urinary tract infections with appropriate antibiotics. In chronic cases, management of CKD according to IRIS guidelines is essential.

The prognosis for hydronephrosis varies widely. If the obstruction is acute and relieved promptly (within 24-48 hours), renal function may recover significantly, and the prognosis is good. However, if obstruction persists for more than 7 days, irreversible renal damage occurs, and the prognosis is guarded. In cases of unilateral hydronephrosis with a healthy contralateral kidney, the prognosis is generally good after nephrectomy or relief of obstruction. Bilateral obstruction carries a poor prognosis if not treated emergently. Underlying causes also influence prognosis: urolithiasis has a fair to good prognosis with appropriate management, while neoplasia has a poor prognosis due to high recurrence and metastasis rates. Chronic hydronephrosis leading to CKD has a guarded prognosis, with progression to end-stage renal failure over months to years. Negative prognostic indicators include severe azotemia at presentation, marked parenchymal thinning, and concurrent pyelonephritis.

Follow-up is essential to monitor renal function and detect recurrence. After treatment, re-evaluate the patient at 1, 2, 4, and 8 weeks, then every 3-6 months. Serial bloodwork (creatinine, BUN, SDMA, electrolytes) and urinalysis should be performed. Blood pressure should be measured regularly. Imaging (ultrasound or CT) is recommended at 1 month post-treatment to confirm resolution of hydronephrosis and then every 3-6 months to monitor for recurrence. If a ureteral stent or SUB device is placed, periodic imaging to assess device patency is necessary. Urine cultures should be repeated if infection was present. Dietary and medical management should be adjusted based on IRIS staging. Owners should be educated on signs of recurrence, such as decreased urine output, vomiting, or lethargy.

Pearls: (1) Always consider hydronephrosis in any cat with acute kidney injury; prompt ultrasound is critical. (2) In dogs, a palpable abdominal mass may be a hydronephrotic kidney; do not mistake it for a splenic mass. (3) Use SDMA to detect early renal dysfunction even when creatinine is normal. (4) In cases of ureteral obstruction, consider medical management with prazosin and fluid diuresis for small stones, but do not delay surgery if no improvement in 24-48 hours. (5) When performing nephrectomy, always confirm the contralateral kidney is functional via ultrasound and bloodwork. Pitfalls: (1) Failing to distinguish hydronephrosis from renal cysts; do not aspirate a hydronephrotic kidney without imaging guidance. (2) Overlooking the possibility of bilateral obstruction in a patient with anuria; always image both kidneys. (3) Using only radiography, which may miss early hydronephrosis; ultrasound is essential. (4) Delaying intervention in acute obstruction, leading to irreversible renal damage. (5) Not performing urine culture, leading to untreated pyelonephritis. (6) In cats, not considering SUB device as a viable option for distal ureteral stones.

Drug protocols for hydronephrosis are primarily supportive and directed at underlying causes. For urolithiasis: (1) Antibiotics for urinary tract infection: amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h), enrofloxacin (5-20 mg/kg PO q24h), or cefpodoxime (5-10 mg/kg PO q24h) based on culture and sensitivity. (2) Ureteral relaxants: prazosin (0.5-1 mg/kg PO q8-12h in dogs; 0.25-0.5 mg/kg PO q8-12h in cats) or tamsulosin (0.01-0.03 mg/kg PO q12-24h in dogs). (3) Diuretics: mannitol (0.25-0.5 g/kg IV over 20 minutes) or furosemide (1-2 mg/kg IV or PO q8-12h) to promote urine flow, but use cautiously in obstructed patients. For hypertension: amlodipine (0.05-0.1 mg/kg PO q24h in dogs; 0.625-1.25 mg/cat PO q24h) or enalapril (0.5 mg/kg PO q12-24h). For hyperkalemia: calcium gluconate 10% (0.5-1 ml/kg IV over 10-20 minutes), regular insulin (0.1 U/kg IV) with dextrose (2 g/U insulin), or sodium bicarbonate (1-2 mEq/kg IV slow). For pain management: buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) or fentanyl CRI (2-5 mcg/kg/hr). For CKD management: phosphate binders (e.g., aluminum hydroxide 30-100 mg/kg/day PO divided), erythropoietin (100 U/kg SC three times weekly) if anemic, and potassium supplementation (potassium gluconate 2-4 mEq/100 kcal/day). Always adjust dosages for renal impairment and monitor for drug interactions.

Evidence-based literature on hydronephrosis in veterinary medicine is limited but growing. Key studies include: (1) A retrospective study by Kyles et al. (2005) on ureteral obstruction in cats, which reported that cats with calcium oxalate uroliths had a high rate of recurrence and that early intervention improved outcomes. (2) A study by Berent et al. (2010) on the use of subcutaneous ureteral bypass devices in cats with ureteral obstruction, showing a 95% success rate in relieving obstruction and improved renal function. (3) A consensus statement from the International Renal Interest Society (IRIS) on the management of chronic kidney disease, which provides guidelines for staging and treatment that are applicable to hydronephrosis-induced CKD. (4) A study by Weisse et al. (2018) on ureteral stenting in dogs, demonstrating that stents are effective for benign and malignant obstructions, with a complication rate of 20-30%. (5) Research on the use of SDMA as an early biomarker of renal dysfunction, which is relevant for monitoring hydronephrosis. (6) ACVIM consensus guidelines on the diagnosis and treatment of urinary tract infections, which emphasize the importance of culture and susceptibility testing in cases of pyelonephritis. Overall, the literature supports early aggressive intervention for ureteral obstruction to preserve renal function.